Is there an optimal time to deploy immunotherapies in multiple myeloma?

During the 46th Annual Meeting of the European Society for Blood and Marrow Transplantation (EBMT), the Multiple Myeloma Hub spoke to Meral Beksaç, Ankara University School of Medicine, Ankara, TR, about immunotherapy for MM. We asked, Is there an optimal time to deploy immunotherapies in multiple myeloma?

In this video, Meral Beksaç talks about how the field of immunotherapy has been advancing rapidly in recent years, with novel monoclonal antibodies (mAbs), alone or with drug conjugates, being developed for use at diagnosis and relapse. Patients today can benefit from the use of anti-CD38 mAbs alongside chemotherapy, whether they are eligible for transplant or not. High rates of measurable residual disease negativity can be achieved by using these treatments.

Figure 1. New ESMO guidelines proposal for the treatment of relapsed multiple myeloma, presented by Meral Beksaç at EBMT 2020, courtesy of María-Victoria Mateos.¹

Ab, antibody; CAR, chimeric antigen receptor; dara, daratumumab, dex, dexamethasone; IMiD, immunomodulatory imide drug; PI, proteasome inhibitor; pom, pomalidomide.